Vishruth K Reddy1, Varsha Jain1, Robert J Wilson Ii2, Lee P Hartner3, Mark Diamond3, Ronnie A Sebro2,4,5,6, Kristy L Weber2, Robert G Maki3, Jacob E Shabason1. 1. Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA. 2. Department of Orthopedic Surgery, University of Pennsylvania, Philadelphia, PA, USA. 3. Division of Hematology/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4. Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA. 5. Department of Genetics, University of Pennsylvania, Philadelphia, PA, USA. 6. Department of Biostatistics, Epidemiology and Bioinformatics, University of Pennsylvania, Philadelphia, PA, USA.
Abstract
PURPOSE: Practice patterns for treatment of localized adult pleomorphic rhabdomyosarcoma (PRMS) remain quite variable given its rarity. Current national guidelines recommend management similar to that of other high-grade soft tissue sarcomas (STS), which include surgery with perioperative radiation (RT) with or without chemotherapy. Using the National Cancer Database (NCDB), we assessed practice patterns and overall outcomes of patients with localized PRMS. Patients and Methods. Patients with stage II/III PRMS treated with surgical resection from 2004 to 2015 were identified from the NCDB. Predictors of RT and chemotherapy use were assessed using multivariable logistic regression analysis. The association of radiation and chemotherapy status on overall survival was assessed using Kaplan-Meier and Cox proportional hazards analyses. RESULTS: Of 243 total patients, RT and chemotherapy were not uniformly utilized, with 44% receiving chemotherapy and in those who did not undergo amputation 62% receiving RT. In those who did not undergo amputation, RT was associated with improved survival on both univariate (HR: 0.49, 95% CI 0.32-0.73, P < 0.001) and multivariate analysis (HR: 0.40, 95% CI 0.26-0.62, P < 0.001), corresponding to greater 5-year overall survival (59% vs. 38%, P < 0.001). Chemotherapy was associated with a higher rate of 5-year overall survival (63% vs. 39%, P < 0.001). However, the survival benefit of chemotherapy did not reach statistical significance on multivariate analysis (HR: 0.65, 95% CI 0.41-1.03, P=0.064). Notable predictors of omission of RT included female gender (OR: 0.40, 95% CI 0.22-0.74, P < 0.01) and age ≥ 70 (OR: 0.55, 95% CI 0.30-1.00, P=0.05). Correspondingly, factors associated with omission of chemotherapy included age ≥70 (OR: 0.17, 95% CI 0.08-0.39, P < 0.001). CONCLUSIONS: A significant proportion of patients with localized adult PRMS are not receiving RT. Likewise, use of chemotherapy was heterogeneous. Our findings note potential benefits and underutilization of RT, for which further investigation is warranted.
PURPOSE: Practice patterns for treatment of localized adult pleomorphic rhabdomyosarcoma (PRMS) remain quite variable given its rarity. Current national guidelines recommend management similar to that of other high-grade soft tissue sarcomas (STS), which include surgery with perioperative radiation (RT) with or without chemotherapy. Using the National Cancer Database (NCDB), we assessed practice patterns and overall outcomes of patients with localized PRMS. Patients and Methods. Patients with stage II/III PRMS treated with surgical resection from 2004 to 2015 were identified from the NCDB. Predictors of RT and chemotherapy use were assessed using multivariable logistic regression analysis. The association of radiation and chemotherapy status on overall survival was assessed using Kaplan-Meier and Cox proportional hazards analyses. RESULTS: Of 243 total patients, RT and chemotherapy were not uniformly utilized, with 44% receiving chemotherapy and in those who did not undergo amputation 62% receiving RT. In those who did not undergo amputation, RT was associated with improved survival on both univariate (HR: 0.49, 95% CI 0.32-0.73, P < 0.001) and multivariate analysis (HR: 0.40, 95% CI 0.26-0.62, P < 0.001), corresponding to greater 5-year overall survival (59% vs. 38%, P < 0.001). Chemotherapy was associated with a higher rate of 5-year overall survival (63% vs. 39%, P < 0.001). However, the survival benefit of chemotherapy did not reach statistical significance on multivariate analysis (HR: 0.65, 95% CI 0.41-1.03, P=0.064). Notable predictors of omission of RT included female gender (OR: 0.40, 95% CI 0.22-0.74, P < 0.01) and age ≥ 70 (OR: 0.55, 95% CI 0.30-1.00, P=0.05). Correspondingly, factors associated with omission of chemotherapy included age ≥70 (OR: 0.17, 95% CI 0.08-0.39, P < 0.001). CONCLUSIONS: A significant proportion of patients with localized adult PRMS are not receiving RT. Likewise, use of chemotherapy was heterogeneous. Our findings note potential benefits and underutilization of RT, for which further investigation is warranted.
Authors: Yun Song; Brett L Ecker; Rebecca Tang; Laura Maggino; Robert E Roses; Ronald P DeMatteo; Douglas L Fraker; Giorgos C Karakousis Journal: Surg Oncol Date: 2019-05-21 Impact factor: 3.279
Authors: T A Alvegård; H Sigurdsson; H Mouridsen; O Solheim; B Unsgaard; U Ringborg; O Dahl; A M Nordentoft; C Blomqvist; A Rydholm Journal: J Clin Oncol Date: 1989-10 Impact factor: 44.544
Authors: Jonathan Noujaim; Khin Thway; Robin L Jones; Aisha Miah; Komel Khabra; Rupert Langer; Bernd Kasper; Ian Judson; Charlotte Benson; Attila Kollàr Journal: Anticancer Res Date: 2015-11 Impact factor: 2.480
Authors: Miriam L Hoven-Gondrie; Esther Bastiaannet; Vincent K Y Ho; Barbara L van Leeuwen; Gerrit-Jan Liefers; Harald J Hoekstra; Albert J H Suurmeijer Journal: Ann Surg Oncol Date: 2016-03-08 Impact factor: 5.344